PURPOSE:Aim of this analysis was to compare biochemical no evidence of disease (bNED) rates in intermediate-risk prostate-cancer patients treated at two centres of excellence using different approaches: permanent interstitial brachytherapy (BT) and external beam radiotherapy (EBRT).
MATERIALS AND METHODS: A total of 890 intermediate-risk prostate-cancer patients, who were treated from 1998 to 2008, were identified in the two local databases. In Utrecht 601 patients received I-125 BT applying a dose of 144Gy. In Vienna 289 patients were treated by EBRT, applying a local dose of 70Gy in 105 patients and 74Gy in 184 patients. bNED-rates (Phoenix-definition) were assessed.
RESULTS: Median follow-up was 48months (1-150). 5-Year actuarial bNED-rates were 81% for BT-patients and 75% for EBRT-patients (67% for 70Gy and 82% for 74Gy), respectively. In univariate analysis no difference between BT and EBRT could be detected. In multivariate analysis including tumour-stage, GleasonScore, initial PSA, hormonal therapy and treatment-centre (BT vs. EBRT) only T-stage, GleasonScore and PSA were found to be significant. Additional analysis including radiation dose showed the same outcome.
CONCLUSIONS: Intermediate-risk prostate cancer patients treated by permanent interstitial brachytherapy show biochemical tumour-control-rates which are comparable to EBRT of 74Gy.
Written by:
Goldner G, Pötter R, Battermann JJ, Kirisits C, Schmid MP, Sljivic S, van Vulpen M. Are you the author?
Department of Radiation Oncology, Medical University of Vienna, Austria.
Reference: Radiother Oncol. 2012 Mar 5. Epub ahead of print.
doi: 10.1016/j.radonc.2012.01.016
PubMed Abstract
PMID: 22398311
UroToday.com Prostate Cancer Section